title: Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis.
abstract: New treatments, such as sipuleucel-T and androgen receptor- (AR-) directed therapies (enzalutamide (Enz) and abiraterone acetate (AA)), have emerged and been approved for the management of castration-resistant prostate cancer (CRPC). There are still debates over their efficacy and clinical benefits. This meta-analysis aimed to investigate the efficacy and safety of sipuleucel-T and AR-directed therapies in patients with CRPC. RevMan 5.1 was used for pooled analysis and analysis of publication bias. Seven studies were included in the meta-analysis, with three studies in sipuleucel-T (totally 737 patients, 488 patients in treatment group, and 249 patients in placebo group) and four in AR-directed therapies (totally 5,199 patients, 3,015 patients in treatment group, and 2,184 patients in placebo group). Treatment with sipuleucel-T significantly improved overall survival in patients with CRPC and was not associated with increased risk of adverse event of grade ≥3 (p> 0.05). However, treatment with sipuleucel-T did not improve time-to-progression and reduction of prostate-specific antigen (PSA) level ≥50% was not significantly different from that with placebo. AR-directed therapies significantly improved overall survival in patients with CRPC and improved time-to-progression and reduction of PSA level ≥50%. AR-directed therapies did not increase risk of adverse event of grade ≥3 (p> 0.05).
authors.affiliation: Guangzhou Hospital of Guangzhou Military Region, Guangzhou, China.
authors.forename: Renliang
authors.initials: R
authors.lastname: Yi
authors.affiliation: School of Public Health, Guangzhou Medical University, Guangzhou, China.
authors.forename: Baoxin
authors.identifier: 0000-0002-0205-8850
authors.initials: B
authors.lastname: Chen
authors.affiliation: School of Public Health, Guangzhou Medical University, Guangzhou, China.
authors.forename: Peng
authors.initials: P
authors.lastname: Duan
authors.affiliation: School of Public Health, Guangzhou Medical University, Guangzhou, China.
authors.forename: Chanjiao
authors.identifier: 0000-0001-9248-0715
authors.initials: C
authors.lastname: Zheng
authors.affiliation: School of Public Health, Guangzhou Medical University, Guangzhou, China.
authors.forename: Huanyu
authors.initials: H
authors.lastname: Shen
authors.affiliation: School of Public Health, Guangzhou Medical University, Guangzhou, China.
authors.forename: Qun
authors.initials: Q
authors.lastname: Liu
authors.affiliation: School of Public Health, Guangzhou Medical University, Guangzhou, China.
authors.forename: Chen
authors.initials: C
authors.lastname: Yuan
authors.affiliation: School of Public Health, Guangzhou Medical University, Guangzhou, China.
authors.forename: Weilin
authors.initials: W
authors.lastname: Ou
authors.affiliation: Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
authors.forename: Zhiheng
authors.identifier: 0000-0003-2325-7338
authors.initials: Z
authors.lastname: Zhou
mesh_terms: D000069501:Abiraterone Acetate / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D006801:Humans; D008297:Male; D009570:Nitriles; D010669:Phenylthiohydantoin / Q000031:analogs & derivatives / Q000627:therapeutic use; D017430:Prostate-Specific Antigen / Q000097:blood*; D064129:Prostatic Neoplasms, Castration-Resistant / Q000628:therapy*; D011944:Receptors, Androgen / Q000187:drug effects*; D014020:Tissue Extracts / Q000627:therapeutic use*
chemical_list: C410798:AR protein, human; D000970:Antineoplastic Agents; D001549:Benzamides; D009570:Nitriles; D011944:Receptors, Androgen; D014020:Tissue Extracts; D010669:Phenylthiohydantoin; C511774:sipuleucel-T; C540278:enzalutamide; D017430:Prostate-Specific Antigen; D000069501:Abiraterone Acetate